Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2009

Open Access Poster presentation

P15-25. Preparation for HIV vaccine trials in Africa: barriers and facilitators for the establishment of a community advisory board in Burkina Faso

A Berthe1, N Meda2, IT Traoré2*, J Some2, S Salouka1, L Sanou1, F Some2, J Rouamba1, D Ouedraogo2, G M'Boutiki2, P Mayaud3, N Nagot4 and P Van de perre4

  • * Corresponding author: IT Traoré

Author Affiliations

1 Centre MURAZ, Bobo-Dioulasso, Burkina Faso

2 Projet Vaccin VIH, Site ANRS-UFR/SDS Université de Ouagadougou, Ouagadougou, Burkina Faso

3 Clinical Research Unit, London School of Hygiene & Tropical Medicine, London, UK

4 Université Montpellier 1, EA 4205, Montpellier, France

For all author emails, please log on.

Retrovirology 2009, 6(Suppl 3):P226  doi:10.1186/1742-4690-6-S3-P226

The electronic version of this article is the complete one and can be found online at: http://www.retrovirology.com/content/6/S3/P226


Published:22 October 2009

© 2009 Berthe et al; licensee BioMed Central Ltd.

Background

Involvement of community level stakeholders in the future HIV vaccine trials is essential to ensure that rights, views, concerns, needs and expectations of the target population are fully taken into account in all phases of their implementation. We carried out a multicomponent situation analysis in two future urban sites in Burkina Faso to identify the proper way to setting up a CAB competent to accompany the trials.

Methods

HIVTAB project is funded by European and Developing Countries Clinical Trials Partnership in Tanzania and partly by French National Agency for AIDS Research (ANRS) in Burkina Faso to strengthen research capacities in preparation to future HIV vaccine trials. Social science methods were applied in recruiting of 23 key informants for in-depth interviews and 03 focus groups discussions between investigators and representatives of community-based NGOs were conducted.

Results

Since 2007 Sidaction provided support to a Network of NGO'S involved in protection of research participants. Also ANRS supports clinical trials in Burkina properly shaped by ANRS ethics charter. The community's leaders want the New CAB to be built around Sidaction initiative. They also prefer one CAB for all the research projects fully or partly managed by the ANRS in Burkina Faso. This CAB will provide impartial witnesses and advice on research design, implementation and dissemination of findings to the community. To protect the confidentiality of studies participants, all members of CAB will sign a confidentiality agreement. The community's representatives want to charge all the projects, particularly the HIVTAB-Project for all the fees related to the implementation of the CAB.

Conclusion

The EDCTP-funded HIVTAB project, by establishing a CAB will enhance community involvement in preparation for future HIV vaccine trials. Nevertheless the funding sources of this CAB and the qualification of community representatives need further discussions and clarifications to not jeopardize its independence and credibility.